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The reauthorization of the Safe Drinking
Water Act of 1996 requires the U.S.
Environmental Protection Agency (EPA) to
develop a priority list of chemicals present in
drinking water and to conduct research into the
modes and mechanisms of action by which
they produce adverse effects (Safe Drinking
Water Act Amendments of 1996). Disinfection
by-products are included in the priority list.
The haloacetic acids, along with the tri-
halomethanes and haloacetonitriles, are the dis-
infection by-products found at the highest
concentrations in drinking water after chlorine
disinfection of surface waters (Krasner et al.
1989). Dichloroacetic acid (DCA) may occur
in drinking water at concentrations > 100 µg/L
(Uden and Miller 1983) and has median con-
centrations in the 15–19 µg/L range (Fair
1996; Krasner at al. 1989).
The carcinogenicity of DCA in the liver of
the male and female B6C3F1 mouse and the
F344 male rat has been well demonstrated
(Bull et al. 1990; Daniel et al. 1992; DeAngelo
et al. 1991, 1996, 1999; Herren-Freund et al.
1987; Pereira 1996). The question arose
whether DCA was promoting the outgrowth
of initiated cells already present in the liver
because the male B6C3F1 mouse has a high
rate of spontaneous liver tumor formation, and
prior initiation with a genotoxic carcinogen
was not required for DCA-induced liver tumor
formation (DeAngelo et al. 1991). More
recent data for the female B6C3F1 mouse and
for the C3H and C57BL parental strains
revealed a biphasic dose–response curve for the
number of carcinomas (CAs) per liver
(DeAngelo 2000b; DeAngelo et al. 1996,
1999, unpublished oberservations). There was
an increase in the number of CAs for the male
B6C3F1 and C3H mouse, strains with high
spontaneous tumor rates, when animals were
given 0.5 g/L DCA. In contrast, no increase in
the number of CAs was seen at 0.5 g/L in ani-
mals with a low-background spontaneous CA
rate (male C57BL mouse and female B6C3F1
mouse), indicating an association between the
background tumor incidence and the CA
response at 0.5 g/L DCA. Concentrations
≥ 0.5 g/L resulted in a steeper dose–response
curve. At the highest concentrations tested,
3.5–5 g/L DCA, there were no differences
between strains or sexes in the CA multiplicity
respective of the spontaneous tumor back-
ground rate (DeAngelo 2000b; DeAngelo et
al. 1996, 1999). Although high concentrations
(> 2 g/L) of DCA induced gene mutations and
chromosomal damage (clastogenesis) in several
in vivo and in vitro test systems (DeMarini et
al. 1994; Fuscoe et al. 1995; Harrington-Brock
et al. 1998; Leavitt et al. 1997), the role of
genotoxicity in the DCA-induced carcinogenic
process in vivo has not been clearly defined
(Chang et al. 1992; Fox et al. 1996; Giller et
al. 1997; Kopﬂer et al. 1985).
Much evidence has been put forth to sup-
port the concept that DCA is acting through
nongenotoxic mechanisms at the lower con-
centrations (0.5 g/L and 1.0 g/L) that enhance
liver neoplasia (International Life Sciences
Institute 1997; Klaunig et al. 2000). For exam-
ple, DCA treatment induced signiﬁcant effects
during the first 30 days of exposure, before
development of hepatic lesions. Effects of
DCA treatment on B6C3F1 mouse liver dur-
ing the ﬁrst 30 days of exposure to drinking
water containing either 0.5 g/L or 5.0 g/L
included induction of hypertrophy (Carter et
al. 1995a); alteration in nuclear size and ploidy
(Carter et al. 1995a); inhibition of hepatocyte
proliferation (Carter et al. 1995a; DeAngelo
2000a); and decreased apoptosis (Snyder et al.
1995). Hepatocyte hypertrophy reﬂected accu-
mulation of glycogen and peroxisome prolifer-
ation (Bull et al. 1990; DeAngelo et al. 1989).
DCA also induced the formation of foci of
phenotypically altered cells before the develop-
ment of benign or malignant hepatic neo-
plasms (Bull et al. 1990; DeAngelo et al. 1991,
1996). These foci of cellular alteration were
integrated into the normal architecture of the
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Dichloroacetic acid (DCA) is carcinogenic to the B6C3F1 mouse and the F344 rat. Given the car-
cinogenic potential of DCA in rodent liver and the known concentrations of this compound in
drinking water, reliable biologically based models to reduce the uncertainty of risk assessment for
human exposure to DCA are needed. Development of such models requires identification and
quantification of premalignant hepatic lesions, identification of the doses at which these lesions
occur, and determination of the likelihood that these lesions will progress to cancer. In this study
we determined the dose response of histopathologic changes occurring in the livers of mice exposed
to DCA (0.05–3.5 g/L) for 26–100 weeks. Lesions were classified as foci of cellular alteration
smaller than one liver lobule (altered hepatic foci; AHF), foci of cellular alteration larger than one
liver lobule (large foci of cellular alteration; LFCA), adenomas (ADs), or carcinomas (CAs).
Histopathologic analysis of 598 premalignant lesions revealed that a) each lesion class had a pre-
dominant phenotype; b) AHF, LFCA, and AD demonstrated neoplastic progression with time; and
c) independent of DCA dose and length of exposure effects, some toxic/adaptive changes in non-
involved liver were related to this neoplastic progression. A lesion sequence for carcinogenesis in
male B6C3F1 mouse liver has been proposed that will enable development of a biologically based
mathematical model for DCA. Because all classes of premalignant lesions and CAs were found at
both lower and higher doses, these data are consistent with the conclusion that nongenotoxic mech-
anisms, such as negative selection, are relevant to DCA carcinogenesis at lower doses where DCA
genotoxicity has not been observed. Key words: B6C3F1 mice, dichloracetic acid, drinking water
disinfection by-products, hepatocarcinogenicity, histopathology, liver toxicity. Environ Health
Perspect 111:53–64 (2003).  [Online 2 December 2002]
doi:10.1289/ehp.5442 available via http://dx.doi.org/tissue and did not show expansive growth.
Immunohistochemical techniques demon-
strated that large foci of cellular alteration
(LFCA; formerly called hyperplastic nodules)
were putative preneoplastic lesions in the pro-
gression of DCA-induced hepatocarcinogene-
sis in both male B6C3F1 mice and male F344
rats (Richmond et al. 1991, 1995). The pres-
ence of isolated, highly dysplasic hepatocytes in
male B6C3F1 mice chronically exposed to
DCA suggested another direct neoplastic con-
version pathway (Carter et al. 1995a, 1995b).
The relevance of these preneoplastic changes
for DCA-induced carcinogenesis has not been
tested by statistical methods.
The potential risks of human exposure to
DCA are indicated by a) the carcinogenic
potential of DCA in rodent liver; b) the
known concentrations of this compound in
drinking water; and c) epidemiologic studies
reporting that drinking water sources con-
taining high concentrations of disinfection
by-products are associated with an increased
human cancer risk (Morris et al. 1992).
However, because of the susceptibility of the
untreated male B6C3F1 mouse to develop-
ment of hepatocellular neoplasms and the
high concentrations of DCA required to
increase the prevalence of CA (3–4 orders of
magnitude above the concentrations in drink-
ing water), a reliable biologically based dose–
response model to reduce the uncertainty in
the risk assessment for human exposure to
DCA is needed (Rabinowitz et al. 2000,
2001). Such a biologically based pharmaco-
dynamic model will relate fundamental cellu-
lar processes to the epidemiology of cancer in
animal and human populations and help to
extrapolate across species, from mice to
humans, and from high-dose experimental
conditions to low dose environmental expo-
sures (Travis 1988). A biologically based
dose–response model for DCA should
include an analysis of the preneoplastic
changes induced in hepatocytes by DCA and
the stability of these changes; the dose at
which these preneoplastic changes occur and
the shape of the dose–response curve; and the
likelihood that the preneoplastic changes will
develop into neoplasia.
To begin addressing these questions, the
present histopathologic analysis includes classi-
ﬁcation, quantiﬁcation, and statistical analysis
of hepatic lesions arising in male B6C3F1 mice
receiving DCA at doses as low as 0.05 g/L for
100 weeks and at 0.5, 1.0, 2.0, and 3.5 g/L for
between 26 and 100 weeks (DeAngelo et al.
1999). As recently recommended (Harada et
al. 1999), the analysis includes a separation of
preneoplastic and benign hepatic lesions into
subtypes as well as a grouping of subtypes. As a
result of this analysis, a model for DCA-
induced carcinogenesis has been developed
that lends itself to testing by mathematical
means (Rabinowitz et al. 2000, 2001).
Histopathologic analysis of the toxic and
adaptive responses to DCA in the male
B6C3F1 mouse liver reveals that negative
selection of cells with a new state of differenti-
ation is a probable mechanism for DCA hepa-
tocellular carcinogenesis in this model (Farber
1990; Farber and Rubin 1991; Harada et al.
1999; Maronpot 1991).
Materials and Methods
Tissues. Tissues were from a previously pub-
lished U.S. EPA study of the hepatocarcino-
genicity of DCA in the male B6C3F1 mouse
(DeAngelo et al. 1999). In that U.S. EPA
study, weanling male B6C3F1 mice, 28–30
days of age, were separated into the 0 (con-
trol), 0.5, 1, 2, and 3.5 g/L DCA dose groups
having 53, 55, 71, 55, and 46 mice, respec-
tively. A second control group containing 30
mice and the 0.05 g/L DCA dose group (35
mice) were started 1 month later. Time-
weighted water consumption was calculated
over the interim and total dosing period by
dividing the amount of water used over a par-
ticular time interval by the total weight of the
mice in the cage and expressed as milliliters per
kilogram per day. Multiplying the water con-
sumption by the measured DCA concentra-
tion yielded mean daily doses (MDD) of 0, 8,
84, 168, 315, and 429 mg/kg/day (DeAngelo
et al. 1999). Groups of 10 animals in each
DCA dose group with the exception of 0.05
g/L DCA were euthanized at 26, 52, and 78
weeks. There were 34 unscheduled deaths.
The remaining animals were euthanized
between 90 and 100 weeks. All aspects of these
studies were conducted in facilities certiﬁed by
the American Association for Accreditation of
Laboratory Animal Care in compliance with
the guidelines of that association and the
National Health and Environmental Effects
Research Laboratory Institutional Animal Care
and Use Committee.
Histopathology. Two blocks from each lobe
and all lesions found at autopsy were preserved
in 10% neutral buffered formalin for 24 hr and
processed routinely. Slides were prepared and
stained with hematoxylin and eosin (H&E).
Histopathologic analysis: diagnostic crite-
ria for hepatocellular changes. We analyzed
1,355 liver specimens from 327 mice for
histopathologic changes. Classification of
hepatic lesions was based on the National
Toxicology Program classification and
nomenclature and on previously described
histopathogenesis of mouse hepatocellular
tumors (Frith and Ward 1979; Harada et al.
1999; Maronpot 1991; Ward 1984).
Altered hepatic foci (AHF) have been
deﬁned as histologically identiﬁable clones of
cells within an organ differing phenotypically
from the normal parenchyma (Maronpot
1991). AHF were groups of cells smaller than a
liver lobule with cytologic changes (clear cell,
spindle cell, dysplasia) or changes in staining
characteristics. AHF did not compress the
adjacent liver and might include portal triads.
Large foci of cellular alteration (LFCA)
were lesions larger than a liver lobule that did
not compress the adjacent liver but had alter-
ations in architecture and staining or cellular
characteristics. These lesions have previously
been referred to as hyperplastic nodules (Bull
et al. 1990; Carter et al. 1995b; DeAngelo et
al. 1991, 1996; Richmond et al. 1991, 1995;
Ward 1984). The present designation of these
lesions as LFCA is to avoid confusion with
non-neoplastic proliferative lesions termed
“hepatocellular hyperplasia” that occur sec-
ondary to hepatic degeneration/necrosis or
neoplasia (Harada et al. 1999). LFCA fre-
quently retained portal triads.
Adenomas (ADs) showed growth by
expansion resulting in displacement of portal
triads and compression of adjacent normal
tissue. ADs had both alterations in liver archi-
tecture and staining or cellular characteristics.
Carcinomas (CAs) were composed of cells
with a high nuclear-to-cytoplasmic ratio and
with nuclear pleomorphism and atypia that
showed evidence of invasion into the adjacent
tissue. These lesions frequently showed a tra-
becular pattern characteristic of mouse hepa-
tocellular CAs. CAs that were metastatic or
multinodular (CA within CA) were also
found in some livers.
Tinctorial and cellular classiﬁcation of pre-
neoplastic lesions. To evaluate lesion sequence,
we initially subclassified 598 premalignant
hepatic lesions, according to Ward, as
basophilic, eosinophilic, clear cell, or mixed cell
(Frith and Ward 1979; Ward 1984). To sim-
plify the data for statistical analysis, we grouped
lesions into three primary types: eosinophilic,
basophilic and/or clear cell, and dysplastic.
Eosinophilic lesions included lesions that
were eosinophilic but could also have clear
cells, spindle cells, or hyaline cells. Basophilic
lesions were grouped with clear cell and mixed
cell (i.e., mixed basophilic, eosinophilic, hya-
line, and/or clear cells) lesions. This grouping
was necessary because many lesions had both a
basophilic and clear cell component, and a
few (< 10%) had an eosinophilic or hyaline
component. Lesions with foci of cells display-
ing nuclear pleomorphism, hyperchromasia,
prominent nucleoli, irregular nuclear borders,
and/or altered nuclear to cytoplasmic ratios
were considered dysplastic irrespective of their
tinctorial characteristics.
Because tinctorial and cytologic character-
izations can be subject to error due to staining
techniques and observer subjectivity, the fol-
lowing approaches were taken to standardize
the data: a) all H&E stains were performed in
one laboratory using the same reagents and
methods; b) the slides were reviewed by two
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headed microscope; c) the observers were
blinded to the treatment groups; and d) the
slides were reviewed multiple times.
We evaluated the histologic sections of
livers from treated and control animals for
evidence of toxic or adaptive responses.
These changes included: necrosis, glycogen
accumulation (i.e., rarefaction), cytomegaly,
steatosis (i.e., lipidosis), atypical nuclei, and
enlarged nuclei. Zonality of the changes was
noted. The histopathologic evaluation of each
slide was entered into a database (Q&A;
Symantec Corporation, Cupertino, CA) and
the data were sorted according to DCA dose,
lesion class, and subclass.
Statistical analysis. We analyzed the num-
ber of lesions per animal using log-linear
Poisson regression with dose and time effects
in the model (Kleinbaum et al. 1982). Linear
trends were considered. At each necropsy time,
the number of lesions per animal at each dose
level was compared to the number of lesions
per animal in the control group, again using
log-linear Poisson regression. We analyzed the
incidence of toxic or adaptive responses (e.g.,
enlarged nuclei) in mouse liver using logistic
regression with dose and time effects in the
model (Kleinbaum et al. 1982). Linear trends
were considered. At each necropsy time, inci-
dence of toxic or adaptive responses at each
dose level was compared to the incidence of
these responses in the control group using an
exact chi-square analysis (Kleinbaum et al.
1982). All statistical analyses were done using
SAS software (SAS Institute, Inc., Cary, NC).
Results
Quantification of premalignant lesions and
their subclasses. Premalignant hepatic
lesions (Figure 1) were separated into three
classes based on three cellular phenotypes:
eosinophilic, basophilic and/or clear cell, and
dysplastic. Phenotypic diversity and hetero-
geneity of cell populations within hepatic
lesions increased from AHF to LFCA and to
AD (Table 1, Figure 2). Histopathologic
analysis of 598 premalignant lesions revealed
that AHF, LFCA, and ADs demonstrated
neoplastic progression by the presence of foci
of dysplastic cells morphologically similar to
cells within hepatocellular CAs (Figure 1)
and that each class of premalignant hepatic
lesion had a predominant phenotype (Tables
1 and 2, Figure 2).
Of the 318 AHF observed in the random
histologic sections of liver, 57% were
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Figure 1. Neoplastic progression in B6C3F1 mouse liver. (A) Low-power photomicrograph of an AHF in a
control mouse, which is recognizable as dysplastic under higher power (magniﬁcation, 63×; bar = 100 µm).
(B) Higher magnification of AHF in (A) illustrating dysplasia including nuclear enlargement, increased
nuclear/cytoplasmic ratio, nuclear hyperchromasia, variation in nuclear size and shape, irregular nuclear
borders, and nucleoli that are increased in size and number with irregular borders (magniﬁcation, 250×; bar
= 100 µm). (C) LFCA in a liver from a mouse treated with 1 g/L DCA; note irregular border and lack of com-
pression at edge (magniﬁcation, 63×; bar = 100 µm). (D) Higher magniﬁcation of LFCA in (C) illustrating a
focus of dysplastic cells within the LFCA (magniﬁcation, 400×; bar = 100 µm). (E) Edge of a large AD from a
mouse treated with 3.5 g/L DCA, demonstrating compression of adjacent parenchyma and “pushing” border
of lesion (magniﬁcation, 63×; bar = 100 µm). (F) Higher magniﬁcation of AD in (E) illustrating dysplastic cells
(magniﬁcation, 400×; bar = 100 µm). (G) Tripolar mitosis and atypical cells adjacent to normal hepatocytes in
a section of normal liver from a mouse treated with 3.5 g/L DCA (magniﬁcation, 400×; bar = 100 µm). (H) CA
from a mouse treated with 0.05 g/L DCA; note similarity between cells in this CA and the dysplastic cells
found in the AHF, LFCA, AD, and normal liver illustrated in (B,D, F, and G) (magniﬁcation, 250×; bar = 100 µm).
Table 1. Subclasses of premalignant hepatic lesions
shown as percent.
Lesion type
AHF LFCA AD
Cellular phenotype (n = 318) (n = 145) (n = 135)
Dys 12.6 32.4 23
(n = 40) (n = 47) (n = 31)
B/CC 30.8 63.5 51.8
(n = 98) (n = 92) (n = 70)
E 56.6 4.1 25.2
(n = 180) (n = 6) (n = 34)
Abbreviations: Dys, dysplastic; B/CC, basophilic and/or
clear cell; E, eosinophilic. A total of 1,355 liver sections
from 327 mice with 598 premalignant lesions were exam-
ined microscopically. Premalignant hepatic lesions were
classified according to size and growth pattern as AHF,
LFCA, or ADs and grouped according to cellular pheno-
type and staining characteristics. Grouping, which was for
purposes of statistical analysis, combined several sub-
classes as shown in Figure 2.eosinophilic, 31% were basophilic and/or
clear cell, and 13% were dysplastic (Table 1,
Figures 1 and 2). These small lesions were not
phenotypically diverse (Figure 2).
Only 4% of the LFCA were eosinophilic
(Table 1). Sixty-four percent of the LFCA
were basophilic and/or clear cell. Of these
basophilic and/or clear cell LFCA, 62 (67%)
retained portal triads (Figure 2B). This is in
contrast to AHF, where only 4/98 (4%) of
the basophilic and/or clear cell altered
hepatic foci had portal triads (Figure 2B).
Therefore, analysis of cellular phenotype
demonstrated that basophilic and/or clear
cell AHF had enhanced growth potential
leading to formation of LFCA. Most (89%)
of the LFCA with dysplasia had a basophilic
and/or clear cell component, and 25/47
(53%) of the dysplastic LFCA retained por-
tal triads (Figure 2C), indicating that
basophilic and/or clear cell LFCA retaining
portal triads had malignant potential. This
conclusion was strengthened by the finding
of portal triads in some CAs.
Adenomas were the most phenotypically
diverse premalignant lesions (Figure 2). Of
the ADs, 25% were eosinophilic (Table 1).
Fifty-two percent of the ADs were basophilic
and/or clear cell (Table 1), but only 15/70
(21%) had portal triads (Figure 2B). The
majority of ADs with areas of dysplasia or CA
(68%) had a basophilic and/or clear cell com-
ponent, but only 4/31 (13%) had portal triads
(Figure 2C). In contrast to dysplastic LFCA,
in which only 8/47 (17%) had an eosinophilic
component, 10/31 (32%) of the dysplastic
ADs had some eosinophilic cells.
Lesion sequence. Based on prevalence and
diversity in each premalignant subclass, three
lesion sequences leading to CAs in the livers
of male B6C3F1 mice have been proposed.
Figure 3 shows the three pathways by which
the premalignant hepatic lesions progressed
from initiated cells to CAs based upon the
histopathologic data.
In the first carcinogenic sequence,
eosinophilic AHF developed into ADs and
then to CAs (Figure 3). Evolution of
eosinophilic AHF to eosinophilic ADs and
conversion of eosinophilic ADs to CAs were
infrequent events (Table 1). Although 57%
(180/318) of the AHF were eosinophilic, only
25% (34/135) of the ADs were eosinophilic
and without evidence of neoplastic progres-
sion. Only 7% (10/135) of the ADs had both
eosinophilic cells and evidence of dysplasia.
The second carcinogenic sequence (Figure
3, Table 1) was from basophilic and/or clear
cell AHF to basophilic and/or clear cell
LFCA. This was the predominant sequence
observed. Basophilic and/or clear cell LFCA
retaining portal triads progressed to CAs
directly, and basophilic and/or clear cell
LFCA without portal triads progressed to
ADs and then to CAs. Thirty-two percent
(47/145) of the LFCA had foci of dysplasia or
CA, whereas 52% (70/135) of the ADs were
basophilic and/or clear cell without evidence
of neoplastic progression, and 16% (21/135)
of the ADs were basophilic and/or clear cell
with foci of dysplasia (Table 1, Figure 2).
In the third carcinogenic sequence
(Figure 3), hepatic CAs in DCA-treated ani-
mals developed from a single initiated cell
(Figure 4), which, by promotion and clonal
expansion, led to dysplastic AHF and then,
by promotion and progression, to CAs.
Thirteen percent of the AHF were associated
with this lesion sequence (Table 1).
The effect of DCA treatment on the out-
growth and progression of hepatic lesions. DCA
enhanced the incidence of animals with pre-
malignant hepatic lesions (Table 2) and lesion
outgrowth (lesions per animal). To determine
the effect of DCA on neoplastic progression in
male B6C3F1 mouse liver, the number of
hepatic lesions per animal was statistically eval-
uated using log-linear Poisson regression analy-
sis with time and dose effects in the model
(Tables 3 and 4) (Kleinbaum et al. 1982). At
each time interval, the number of lesions per
animal at each dose level was compared to the
number of lesions per animal in the control
group using log-linear Poisson regression.
DCA (0.05–3.5 g/L) increased the number
of lesions per animal relative to animals receiv-
ing distilled water and shortened the time to
development of all classes of hepatic lesions
(Figures 5 and 6, Table 3). Figure 5 illustrates
the dose response to five concentrations of
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Table 2. Number of lesions/number of animals in group and incidence of premalignant hepatic lesions
(% animals) at given doses of DCA and overall.
Lesion class, subclass  Control 0.05 g/L 0.5 g/L 1.0 g/L 2.0 g/L 3.5 g/L Overall
AHF
Dys 4/80 1/33 3/55 7/65 9/51 5/43 29/327
(5) (3) (5.5) (10.8) (17.6) (11.6) (8.9)
B/CC 3/80 1/33 2/55 12/65 17/51 12/43 47/327
(3.8) (3) (3.6) (18.5) (33.3) (27.9) (14.4)
E 6/80 6/33 18/55 22/65 19/51 20/43 91/327
(7.5) (18.2) (32.7) (33.8) (37.3) (46.5) (27.8)
LFCA
Dys 1/80 2/33 7/55 14/65 8/51 7/43 39/327
(1.2) (6.1) (12.7) (21.5) (15.7) (16.3) (11.9)
B/CC 4/80 1/33 7/55 17/65 16/51 8/43 53/327
(5) (3) (12.7) (26.2) (31.4) (18.6) (16.2)
E 0/80 0/33 0/55 1/65 1/51 2/43 4/327
(0) (0) (0) (1.5) (2) (4.7) (1.2)
ADs
Dys 5/80 3/33 4/55 7/65 2/51 7/43 28/327
(6.2) (9.1) (7.3) (10.8) (3.9) (16.3) (8.6)
B/CC 7/80 10/33 2/55 9/65 11/51 18/43 57/327
(8.8) (30.3) (3.6) (13.8) (21.6) (41.9) (17.4)
E 2/80 0/33 2/55 6/65 7/51 10/43 27/327
(2.5) (0) (3.6) (9.3) (13.7) (23.3) (8.3)
Abbreviations: B/CC, basophilic and/or clear cell; Dys, Dysplastic; E, eosinophilic. Controls received 0 g/L DCA. The
results are pooled over all lengths of exposure to illustrate the effect of dose.
Figure 2. Phenotypic diversity and heterogeneity of cell populations within the three major subclasses of premalignant hepatic lesions, which increased with neoplas-
tic progression. Abbreviations: Dys, dysplastic; B, basophilic; CC, clear cell; E, eosinophilic; H, hyaline cells; S, spindle cell changes, T, portal triads. (A) Eosinophilic
lesions included 180 AHF, 6 LFCA, and 34 ADs. (B) B/CC lesions included 98 AHF, 92 LFCA, and 70 ADs. (C) Dys lesions included 40 AHF, 47 LFCA, and 31 ADs.
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Dys + B/CC + TDCA relative to controls at 100 weeks. Figure
6 compares hepatic lesion development with
length of exposure (time) up to 2 years in low
dose (0.5 g/L and 1.0 g/L) and high dose (2.0
and 3.5 g/L) animals. Separation into high and
low doses was based on previously reported
CA incidences (DeAngelo et al. 1999) and on
this independent review of the slides (Figure
5D). Table 3 gives the p-values for the DCA
dose and time effects. Poisson regression analy-
sis of the development of hepatic lesions with
DCA dose and length of exposure indicated
that all hepatic lesions were significantly
related to either DCA dose or length of expo-
sure in male B6C3F1 mouse liver.
DCA dose effects. All classes of hepatic
lesions were found in groups of animals receiv-
ing drinking water containing 0–3.5 g/L DCA
(Table 2, Figure 5). Although this analysis
could not distinguish between spontaneously
arising lesions and additional lesions of the
same type induced by DCA, only lesions of the
kind that were found spontaneously in control
liver were found in increased numbers in ani-
mals receiving DCA. The only subclass of
lesion not found in control animals was
eosinophilic LFCA, and DCA did not enhance
the outgrowth of these lesions (Table 4).
Development of eosinophilic, basophilic
and/or clear cell and dysplastic AHF was signif-
icantly related to DCA dose at 100 weeks and
overall adjusted for time (Figure 5A, Table 3).
Eosinophilic AHF were the most frequently
found lesions at 100 weeks (Figure 5).
Development of eosinophilic AHF was margin-
ally related to DCA dose at 52 weeks and
highly correlated to DCA dose at 78 and 100
weeks (Figures 5A and 6A, Table 3). Poisson
regression analysis indicated three signiﬁcant
differences in the number of AHF per animal
in DCA-treated animals relative to controls: a)
significantly more eosinophilic AHF were
found in mice receiving 0.5, 1.0, 2.0, and 3.5
g/L DCA; b) signiﬁcantly more basophilic/clear
cell AHF were found in mice receiving 1.0, 2.0,
and 3.5 g/L DCA; and c) the number of dys-
plastic AHF was signiﬁcantly different only in
mice receiving 2.0 g/L DCA.
Basophilic and/or clear cell LFCA were the
predominant subclass found at all DCA dose
levels and in controls. The number per animal
was highly related to DCA dose at 100 weeks
and overall adjusted for time (Figure 5B, Table
3). The number of dysplastic LFCA per ani-
mal was also highly related to the DCA dose at
100 weeks (Table 3). The number of both
basophilic and dysplastic LFCA per animal
increased rapidly from 0 to 1.0 g/L DCA and
then plateaued between 1.0 and 3.5 g/L. In
mice receiving 0.05, 1.0, 2.0, or 3.5 g/L DCA,
both the number of basophilic and/or clear cell
and the number of dysplastic LFCA per ani-
mal were signiﬁcantly different from controls.
ADs were the most frequently occurring
lesions in control mice. The number of
basophilic and/or clear cell ADs per animal
was signiﬁcantly related to dose at 52 and 100
weeks and overall adjusted for time (Figure
5C, Table 3). Development of eosinophilic
ADs was significantly related to dose at 52,
78, and 100 weeks and overall (Table 3).
Dysplastic ADs were related to dose only at
52 weeks. The number of basophilic ADs per
mouse differed signiﬁcantly from controls in
animals receiving 0.05, 2.0, and 3.5 g/L
DCA, and the number of eosinophilic ADs
per mouse differed signiﬁcantly from controls
in animals receiving 2.0 or 3.5 g/L DCA.
As previously reported, development of
CAs in DCA-treated mice was highly corre-
lated with both DCA dose and length of expo-
sure (p = 0.0001) (DeAngelo et al. 1999). This
independent review of slides from that study
indicated that the number of CAs per animal
was signiﬁcantly related to dose at 78 and 100
weeks and overall adjusted for time (Figures
5D and 6D, Table 3). This is consistent with
the evolution of CAs from the dysplastic ADs
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Eosinophilic AHF
Basophilic AHF Initiated cell
Dyplastic AHF
Basophilic LFCA
Basophilic AD Clear cell AD
Eosinophilic AD
CA
Basophilic LFCA
with CA
Figure 3. Proposed lesion sequences in male B6C3F1 mouse liver based on histopathologic analysis of fre-
quency of hepatic lesions found in 327 male B6C3F1 mice (Table 1). The first carcinogenic sequence is
from an initiated cell to an eosinophilic AHF, which progresses to an AD and then to a CA. The second
carcinogenic sequence is from an initiated cell to a basophilic and/or clear cell AHF, which because of a
selective growth advantage develops into basophilic and/or clear cell LFCA. In this model, basophilic
and/or clear cell LFCA with portal triads progress to CAs directly and basophilic and/or clear cell LFCA
without portal triads progress to ADs and then to CAs. The third carcinogenic sequence is from a single
initiated cell, which develops into a dysplastic AHF by clonal expansion and then to a CA.
Figure 4. Examples of atypical cells found in livers of B6C3F1 mice. Incidence of atypical cells in non-involved normal liver was highly associated with the number
of dysplastic LFCA, dysplastic ADs, and CAs per mouse.seen at 52 weeks. Overall, the number of CAs
per animal was significantly different from
controls in mice receiving 0.5, 1.0, 2.0, and
3.5 g/L DCA.
Effect of length of DCA exposure. Both
AHF and ADs were found in DCA-treated
animals at 26 weeks. Basophilic and dysplas-
tic LFCA and CAs were found at 52 weeks,
consistent with their evolution from these
earlier appearing lesions.
Development of basophilic and/or clear
cell AHF was significantly related to the
length of DCA exposure between 26 and 100
weeks in animals receiving 1.0, 2.0, or 3.5
g/L DCA (Figures 5A and 6A, Table 4).
Eosinophilic AHF were related to length of
DCA exposure in animals receiving 0.5, 1.0,
2.0, or 3.5 g/L DCA (Table 4). The number
of basophilic and eosinophilic AHF increased
approximately 3-fold between 52 and 100
weeks. Consistent with the later appearance
of dysplastic AHF, there was a trend for a
relationship between dysplastic AHF and
DCA dose at 78 weeks, and a signiﬁcant rela-
tionship with DCA dose at 100 weeks (Table
3). The relationship between dysplastic AHF
and length of exposure was signiﬁcant only in
mice receiving 2.0 g/L DCA (Table 4).
Development of basophilic and/or clear
cell LFCA was related to the length of expo-
sure to drinking water containing 1.0, 2.0, or
3.5 g/L DCA, and a trend was found at 0.5
g/L (Table 4). The number of dysplastic
LFCA per animal was related to the length of
DCA exposure at 1.0, 3.5, and 0.5 g/L, where
a trend was found (Figures 5B and 6B,
Table 4). Overall, the development of both
basophilic and/or clear cell and dysplastic
LFCA was highly related to both dose and
length of exposure (Tables 3 and 4).
The number of basophilic and/or clear
cell ADs per animal was significantly related
to the length of exposure in mice receiving
2.0 g/L DCA (Table 4). Poisson regression
analysis indicated that when all doses and
exposure lengths were considered, develop-
ment of basophilic and/or clear cell,
eosinophilic, and dysplastic ADs were
related to length of exposure (Table 4,
Figures 5C and 6C).
The number of CAs per animal was sig-
niﬁcantly related to length of exposure at 1.0,
2.0, and 3.5 g/L DCA (Figures 5D and 6D,
Table 4).
Toxic or adaptive responses in the livers of
DCA treated mice. DeAngelo et al. (1999)
recently reported that the hepatocellular CA
incidence and multiplicity in these DCA-
treated mice were a function of mean daily
dose and that there was a signiﬁcant trend for
increasing absolute and relative liver weights
with dose throughout the exposure period.
Here, the incidence of toxic or adaptive
responses in the livers of these mice was evalu-
ated using logistic regression to determine if
early toxic or adaptive hepatic morphologic
changes were associated with DCA-induced
neoplastic progression and hepatocellular car-
cinogenesis. Table 5 presents the overall inci-
dence of toxic or adaptive responses, including
hepatocellular CA, in relation to DCA dose.
Necrosis. Necrosis was found in 11.3% of
the animals in the study and was the least
prevalent toxic or adaptive response (Table 5).
At 26 weeks exposure to 3.5, 2.0, or 1.0 g/L
DCA, focal necrosis was present in 50, 50,
and 80% of the livers, respectively. These
small areas of necrotic hepatocytes were dis-
tributed in the livers without regard to liver
architecture. Three independent reviews of
slides from these animals (DeAngelo et al.
1999; International Life Sciences Institute
1997; and this report) found necrosis ranging
from single-cell necrosis to small clusters of
necrotic hepatocytes, and to occasional pan-
lobular coagulative necrosis in mice receiving
1.0–3.5 g/L DCA for 26 weeks. At 26 weeks,
the incidence of necrosis in mice receiving 1.0,
2.0, or 3.5 g/L DCA was signiﬁcantly differ-
ent from that in controls (p = 0.0071, 0.0325,
and 0.0325, respectively). Focal necrosis was
not present at 26 weeks in animals exposed to
water or to 0.5 g/L DCA. The incidence of
necrosis in treated mice did not differ statisti-
cally from controls at 52 or 78 weeks.
However, necrosis was signiﬁcantly different
from controls after 100 weeks of treatment
with 3.5 g/L DCA (p = 0.0002). Overall,
necrosis was negatively related to length of
exposure and positively related to DCA dose
(Tables 6 and 7). These results are consistent
with the findings of two other pathologists
(DeAngelo et al. 1999; International Life
Sciences Institute 1997) and show that necro-
sis was an early and transitory response.
Rarefaction/glycogen accumulation.
Glycogen accumulation as evidenced by clear
cell changes and diffuse rarefaction (Sanchez
and Bull 1990) was present in 11.9% of the
animals (Table 5). At 26 weeks and 78 weeks
of DCA treatment, clear cell changes were
found focally in the livers; whereas at 52
weeks, a diffuse rarefaction was observed.
The periodic acid Schiff (PAS) reaction was
negative due to dissolution of glycogen in the
aqueous fixative. Rarefaction was not found
in controls and was dose dependent. Animals
receiving 1.0, 2.0, or 3.5 g/L DCA for 52
weeks differed signiﬁcantly from controls (p =
0.0031, 0.0325, and 0.0007, respectively);
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Figure 5. DCA dose response at 100 weeks in B6C3F1 male mice given drinking water containing 0–3.5 g/L
DCA. Lesions were classiﬁed as (A) AHF, (B) LFCA, (C) ADs, or (D) CAs and subclassiﬁed into three major
groups: eosinophilic (E), basophilic and/or clear cell (B/CC), and dysplastic (Dys). Poisson regression
analysis of the development of hepatic lesions with DCA dose indicated that development of B/CC, E, and
Dys AHF; B/CC and Dys LFCA, B/CC, E, and Dys ADs; and CAs, was signiﬁcantly related to DCA exposure in
male B6C3F1 mouse liver.however, glycogen accumulation was found
only in the periportal hepatocytes in mice
given 0.5 g/L DCA. Focal cells did not have
evidence of glycogen accumulation. Glycogen
accumulation was not seen at 100 weeks and
was negatively correlated with length of expo-
sure overall adjusted for dose (Table 7).
Cytomegaly. Enlargement of hepatocytes
(cytomegaly) was found in 17.4% of the ani-
mals (Table 5). Consistent with previous
short-term studies (Carter et al. 1995a),
cytomegaly was present in 90–100% of the liv-
ers of mice given 1.0–3.5 g/L DCA for 26
weeks. When DCA dose groups were com-
bined over length of exposure, the incidence of
cytomegaly was significantly different from
controls in mice receiving 1.0, 2.0, and 3.5 g/L
DCA (p ≤ 0.0001). Overall, cytomegaly was
positively related to DCA dose and negatively
related to length of exposure (Tables 6 and 7).
Steatosis. Accumulation of lipid droplets
(steatosis, lipidosis) was present in some hepa-
tocytes from most groups of mice and in
24.2% of the animals overall (Table 5). The
incidence of steatosis was negatively corre-
lated with dose, reﬂecting the hypolipidemic
effects of DCA (Stacpoole et al. 1978). There
were no incidences of steatosis in six of the
eight groups of animals receiving 2.0 and 3.5
g/L DCA, and this was signiﬁcantly different
overall from controls (p = 0.0001, and
0.0094, respectively, see Table 5). The inci-
dence of steatosis was positively correlated
with age and body weight in controls.
Atypical nuclei. Overall, atypical nuclei
were found in 40.7% of the animals (Table 5,
Figure 4). Atypical nuclei had one or more of
the following characteristics: variable, irregu-
lar, misshapen, enlarged relative to the cyto-
plasm, and/or hyperchromatic. When nuclei
had three or more of these characteristics, they
were considered dysplastic. However, atypical
and dysplastic cells were combined in this
analysis. By 100 weeks exposure, atypical
nuclei were seen in 85, 90.5, and 86% of the
livers from animals exposed to 3.5, 2.0, and
1.0 g/L DCA, respectively, and also in 56, 33,
and 32% of the livers from animals receiving
0.5 or 0.05 g/L DCA and in controls, respec-
tively. Overall, the incidence of atypical nuclei
in liver was signiﬁcantly related to both length
of exposure and DCA dose (Tables 6 and 7).
The combined data indicated that the inci-
dence of atypical nuclei in non-involved liver
differed significantly from controls in mice
receiving 1.0, 2.0, or 3.5 g/L DCA (p =
0.0001, 0.0001, and 0.0079, respectively).
Enlarged nuclei. Enlarged nuclei were
present in livers of animals sacriﬁced through-
out the study and in both control and treated
animals (Table 5). Nuclear enlargement was
related to DCA dose at 100 weeks but not
overall adjusted for time (Table 6). This kary-
omegaly was zonal, being prominent near the
central veins. The incidence of enlarged
nuclei was related to the length of DCA
exposure in animals receiving 0.5, 1.0, 2.0, or
3.5 g/L DCA (Table 7).
Adaptive changes related to neoplastic
progression in DCA-induced hepatocellular
carcinogenesis. Logistic regression analysis
adjusting for DCA dose and length of exposure
was used to evaluate the association between
development of dysplasia or CA and toxic or
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Figure 6. Development of hepatic lesions at 26, 52, 78, or 100 weeks in male B6C3F1 mice exposed to drink-
ing water containing low doses (0.5–1.0 g/L; left) and high doses (2.0–3.5 g/L; right) of DCA. Separation into
low and high doses was based on previously reported CA incidences (DeAngelo et al. 1999) and the present
data (Figure 5D). Lesions were classified as AHF (A), LFCA (B), ADs (C), or CAs (D). Poisson regression
analysis of the development of hepatic lesions with length of exposure to DCA indicated that development
of basophilic and/or clear cell (B/CC), eosinophilic (E), and dysplastic (Dys) AHF; B/CC and Dys LFCA; B/CC,
E, and Dys ADs; and CAs, was signiﬁcantly related to DCA exposure in male B6C3F1 mouse liver. The effect
of length of exposure on development of hepatic lesions was seen at both low and high doses of DCA.
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Weeksadaptive changes. The occurrence of dysplas-
tic AHF was not associated with any toxic or
adaptive response. In contrast, dysplastic
LFCA were significantly related to the pres-
ence of zonal changes, enlarged nuclei, and
atypical nuclei in the adjacent non-involved
liver (p = 0.0002, 0.0025, and 0.0001,
respectively). Steatosis was negatively related
to dysplastic LFCA. Dysplastic LFCA were
not related to necrosis (p = 0.2386), indicat-
ing that these lesions do not represent com-
pensatory, regenerative, or reparative
hyperplasia in this model.
Nuclear atypia in non-involved hepato-
cytes and glycogen accumulation were associ-
ated with dysplastic ADs (p = 0.0045 and
0.0074, respectively). Necrosis was not
related to occurrence of dysplastic ADs (p =
0.5027).
As with dysplastic LFCA, CAs were nega-
tively associated with steatosis (p = 0.0020).
Similar to dysplastic ADs and dysplastic
LFCA, CAs were associated with atypical
nuclei in the adjacent liver (p = 0.0136).
Necrosis was of borderline significance in
relation to the presence of hepatocellular CAs
(p = 0.0553). As necrosis was not associated
with development of dysplastic LFCA or
ADs, this may indicate an effect of necrosis
on the development of CAs directly from dys-
plastic foci (the third lesion sequence).
In summary, some toxic or adaptive
responses associated with DCA exposure in
non-involved male B6C3F1 mouse livers
were related to the neoplastic progression of
LFCA and ADs and to the occurrence of
hepatocellular CAs even after adjusting for
dose and length of exposure effects. The
data (Table 7) demonstrating a negative cor-
relation between some of these responses
(e.g., glycogen accumulation) and length of
DCA exposure indicate adaptation in the
livers of mice exposed to DCA and are con-
sistent with the hypothesis that hepatocellu-
lar carcinogenesis in this model is associated
with negative selection for cells with a new
state of differentiation (Maronpot 1991)
and progressive adaptation and selection
within premalignant hepatic lesions (Carter
et al. 2001a, 2001b).
Discussion
Given the carcinogenic potential of DCA in
rodent liver (Bull et al. 1990; Daniel et al.
1992; DeAngelo et al. 1991, 1996, 1999;
Herren-Freund et al. 1987; Pereira 1996) and
the known concentrations of this compound
in drinking water (Fair 1996; Krasner et al.
1989; Uden and Miller 1983), reliable bio-
logically based models to reduce the uncer-
tainty of risk assessment for human exposure
to DCA are needed. Development of such
models requires identiﬁcation and quantiﬁca-
tion of premalignant hepatic lesions, identiﬁ-
cation of the doses at which these lesions
occur, and determination of the likelihood
that these lesions will progress to cancer. To
address these questions, histopathologic
analysis was conducted for livers and hepatic
lesions arising in B6C3F1 male mice receiving
DCA doses as low as 0.05 g/L for 100 weeks,
and DCA at 0.5, 1.0, 2.0, and 3.5 g/L for
between 26 and 100 weeks (DeAngelo et al.
1999). Nongenotoxic versus potential geno-
toxic effects of DCA can be separated based
on low dose (0.05–1.0 g/L) or low concentra-
tions, where genotoxicity has not been
demonstrated, versus high dose (2–3.5 g/L)
or high concentrations, where gene mutations
and clastogenesis has been observed in several
test systems (Chang et al. 1992; DeMarini et
al. 1994; Ferreia-Gonzalez et al. 1995; Fuscoe
et al. 1995; Harrington-Brock et al. 1998;
Leavitt et al. 1997) (Table 8). This analysis
suggested a model for DCA-induced carcino-
genesis, involving three lesion sequences, that
lends itself to testing by mathematical means
(Rabinowitz et al. 2000, 2001).
The liver of the male B6C3F1 mouse is
highly susceptible to the development of
hepatocellular neoplasms and undergoes a
spectrum of premalignant, benign, and malig-
nant lesions during its lifetime (Harada et al.
1999), suggesting the presence of a population
of initiated cells in the livers of young mice.
With the exception of eosinophilic LFCA, all
of the premalignant lesions seen in the livers
from DCA-treated animals in this study were
seen also in untreated animals, though in
markedly lower numbers, indicating that
DCA enhanced processes otherwise occurring
during the aging process in B6C3F1 mice.
Diagnostic criteria for identifying classes
of preneoplastic and neoplastic hepatocellular
lesions in mouse liver have been described
(Frith and Ward 1979; Harada et al. 1999;
Maronpot 1991; Ward 1984). Bannasch
(1986) defined preneoplasia as being a phe-
notypically altered cell population that has no
obvious neoplastic nature but has a high
probability of progressing to a benign or
malignant neoplasm. Differences in pheno-
type based on cytological features and tinctor-
ial properties in H&E-stained histologic
sections at the light microscopic level reﬂect
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Table 3. Log-linear Poisson regression analysis (p-values) of lesions per animal with effects of DCA dose:
at sequential intervals of DCA exposure and overall adjusted for time (Overall adj). 
Lesion class, subclass 26 weeks 52 weeks 78 weeks 100 weeks Overall adj
AHF
Dys NS — 0.0722a 0.0022 0.0004
B/CC NS 0.0294 0.0006 0.0001 0.0001
EN S 0.0523a 0.0001 0.0001 0.0001
LFCA
Dys — NS — 0.0001 0.0001
B/CC — NS NS 0.0001 0.0001
E— —N S 0.0692a 0.0081
AD
Dys — 0.0236 NS NS NS
B/CC — 0.0007 0.0614a 0.0001 0.0001
E— 0.0131 0.0081 0.0001 0.0001
CA — NS 0.0015 0.0001 0.0001
Abbreviations: B/CC, basophilic and/or clear cell; Dys, Dysplastic; E, eosinophilic; NS, not signiﬁcant. Linear trends were
considered in the analysis. Interim sacrifices included 10 animals/group with variable numbers of animals at the 100-
week sacriﬁce.
ap-Values with marginal signiﬁcance.
Table 4. Log-linear Poisson regression analysis (p-value) of lesions per animal with length of exposure at
given doses of DCA and overall adjusted for dose (Overall adj). 
Lesion class, subclass Control 0.5 g/L 1.0 g/L 2.0 g/L 3.5 g/L Overall adj
AHF
Dys NS — — 0.0120 NS 0.0003
B/CC NS NS 0.0264 0.0080 0.0118 0.0001
EN S 0.0130 0.0024 0.0001 0.0001 0.0001
LFCA
Dys — 0.0676a 0.0235 — 0.0247 0.0001
B/CC — 0.0855a 0.0009 0.0006 0.0067 0.0001
E— — — N S NS NS
AD
Dys NS — NS — NS 0.0072
B/CC NS NS NS 0.0403 NS 0.0006
E— ——NS 0.0605a 0.0028
CA — — 0.0440 0.0001 0.0003 0.0001
Abbreviations: B/CC, basophilic and/or clear cell; Dys, Dysplastic; E, eosinophilic; NS, not signiﬁcant. Controls received 0 g/L
DCA. Linear trends were considered in the analysis. Interim sacriﬁces included 10 animals/group with variable numbers of
animals at the 100-week sacriﬁce.
ap-Values with marginal signiﬁcance.structural differences in cellular organization
at the subcellular level such as increases in
smooth endoplasmic reticulum and/or mito-
chondria (eosinophilia); increases in rough
endoplasmic reticulum and/or free ribosomes
(basophilia); accumulation of glycogen
and/or lipid (clear cells); and changes in
ploidy (enlarged nuclei) (Harada et al. 1999).
Such changes in subcellular organization
reﬂect changes in cell function (i.e., differen-
tiation). Carcinogenesis can be thought of as
resulting in a new state of differentiation that
gives the new phenotype a selective growth
advantage (Farber 1990; Farber and Rubin
1991), or as a form of toxicity where cells
achieve a different steady state from normal
and do not respond to normal homeostatic
mechanisms (Maronpot 1991). Therefore,
phenotypic changes in preneoplastic and neo-
plastic lesions during carcinogenesis should
reveal information about the carcinogenic
process induced by DCA.
The lesion sequences proposed here were
based on the histopathologic evaluation of
essentially two-dimensional (5 µm) histologic
sections. Further sectioning of parafﬁn blocks
indicated that AHF were not always isolated
structures. For example, multiple altered foci
in one section coalesced at a deeper level to
appear as LFCA or ADs, and small AHF dis-
appeared, became larger, or remained the same
size at deeper levels. Acid/base staining charac-
teristics also could vary with section level.
Branching of AHF was proven previously by
three-dimensional reconstruction (Imaida et al.
1989; Ito et al. 1989). These observations indi-
cated that some premalignant hepatic lesions
represent a continuum in space and time, and
emphasized the fact that the probability of
observing a given type of lesion in a random
section of liver depends upon the frequency,
size and shape of the lesion.
Despite these limitations, identification
and quantification of phenotypes of hepato-
cellular lesions in the B6C3F1 male mouse
revealed three lesion sequences during mouse
liver carcinogenesis (Figure 3). The first
lesion sequence was from eosinophilic AHF,
the most frequent lesion observed in this
study, representing 30% (n = 180) of the 598
lesions examined (Table 1). The number of
eosinophilic AHF per animal was signiﬁcantly
different from controls at both low and high
doses of DCA and was signiﬁcantly related to
DCA dose at 100 weeks. Thus, DCA increased
the number of AHF with a predominance of
smooth endoplasmic reticulum and mitochon-
dria. DCA did not promote clonal expansion
of eosinophilic AHF by itself, as indicated by
the facts that eosinophilic LFCA were rare in
DCA treated animals (n = 6; Table 1), were not
related to length of exposure, and were only
marginally related to dose at 100 weeks (Tables
3 and 4). Some eosinophilic AHF developed
into eosinophilic ADs directly, as shown by the
data indicating that 34/135 (25%) of the ADs
were eosinophilic (Table 1). The number of
eosinophilic ADs per mouse differed signifi-
cantly from controls in animals receiving the
highest doses of DCA (2 or 3.5 g/L). Seven
percent (10/135) of the ADs were eosinophilic
with dysplasia or CA, illustrating that
eosinophilic ADs had malignant potential. 
The discrepancy between the number of
eosinophilic AHF and the number of CAs
observed indicated the failure of DCA alone to
promote the neoplastic progression of most
eosinophilic AHF in the male B6C3F1 mouse
except at high doses. Pereira (1996) also found
that DCA induced primarily eosinophilic AHF
in the livers of female mice in a dose-depen-
dent manner. We report that 56.6% of the
AHF in male B6C3F1 mice were eosinophilic
(Table 1), and Pereira (1996) reported that
57.2, 81.8, and 96.7% of the AHF found in
female B6C3F1 mice were eosinophilic in ani-
mals given DCA at 2.0, 6.67, and 20.0
mmole/L, respectively. However, in contrast to
our ﬁndings in the male, where only 25.2% of
the ADs were eosinophilic (Table 1),
90–100% of the neoplasms (ADs and CAs) in
the female were eosinophilic (Pereira, 1996).
This is not surprising because untreated male
and female B6C3F1 mice differ in the inci-
dence of hepatocellular lesions and in AHF
phenotypic distribution (Harada et al. 1999).
The incidence of AHF, ADs, and CAs is
higher in male versus female B6C3F1 mice
from 58 weeks until 168 weeks of age, and this
difference is greatest between 84 and 109
weeks when the incidence of AHF, ADs, and
CAs is 3.9-, 2.3-, and 4.5-fold higher, respec-
tively, in male versus female controls (Harada
et al. 1999). The incidence of mixed cell, clear
cell, basophilic, or eosinophilic AHF ranges
from 2.0 to 4.8% in female control B6C3F1
mice, whereas in the male controls the inci-
dence of clear cell foci is 12.9%, that of
eosinophilic foci is 12.0% while basophilic foci
and mixed cell foci each have a 3.6% incidence
(Harada et al. 1999).
The second carcinogenic sequence was
from basophilic and/or clear cell AHF that
grew into basophilic and/or clear cell LFCA
and progressed to CAs directly. Alternatively,
the basophilic and/or clear cell AHF became
basophilic and/or clear cell LFCA before pro-
gressing to ADs or to CAs. This was the 
predominant sequence found in this study
(Figure 3). The combined total of basophilic
and/or clear cell LFCA and ADs was greater
than the number of basophilic and/or clear cell
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Table 5. Number of animals with response/number of animals in group and incidence of toxic or adaptive
responses (% animals) at given doses of DCA and overall.
Toxic/adaptive
response Control 0.05 g/L 0.5 g/L 1.0 g/L 2.0 g/L 3.5 g/L Overall
Necrosis 2/80 2/33 1/55 13/65 6/51 13/43 37/327
(2.5) (6.1) (1.8) (20) (11.8) (30.2) (11.3)
Glycogen 3/80 0/33 11/55 7/65 6/51 12/43 39/327
(3.8) (0) (20) (10.8) (11.8) (27.9) (11.9)
Cytomegaly 1/80 0/33 0/55 20/65 21/51 15/43 57/327
(1.2) (0) (0) (30.8) (41.2) (34.9) (17.4)
CA 6/80 5/33 6/55 13/65 20/51 16/43 66/327
(7.5) (15.2) (10.9) (20) (39.2) (37.2) (20.2)
Steatosis 21/80 22/33 19/55 14/65 0/51 3/43 79/327
(26.3) (66.7) (34.5) (21.5) (0) (7) (24.2)
Zonal change 9/80 0/33 22/55 39/65 25/51 13/43 108/327
(11.2) (0) (40) (60) (49) (30.2) (33)
Atypical nuclei 18/80 11/33 18/55 36/65 30/51 20/43 133/327
(22.5) (33.3) (32.7) (55.4) (58.8) (46.5) (40.7)
Enlarged nuclei 33/80 13/33 30/55 36/65 23/51 18/43 153/327
(41.2) (39.4) (54.5) (55.4) (45.1) (41.9) (46.8)
Controls received 0 g/L DCA. The results were pooled over all lengths of exposure to illustrate the effect of dose.
Table 6. Logistic regression analysis (p-values) of incidence of toxic or adaptive responses with effects of DCA
dose at sequential intervals of exposure and overall adjusted for time (Overall adj).
Toxic/adaptive
response 26 weeks 52 weeks 78 weeks 100 weeks Overall adj
Necrosis 0.0192 — NS 0.0029 0.0002
Glycogen 0.0745a 0.0010 0.0426 NS 0.0162
Cytomegaly 0.0009 NS NS 0.0001 0.0001
CA — NS 0.0031 0.0001 0.0001
Steatosis NS NS 0.0202b 0.0004b 0.0001b
Zonal change NS NS NS 0.0001 0.0002
Atypical nuclei NS 0.0019 0.0994a 0.0001 0.0001
Enlarged nuclei NS 0.0901a NS 0.0005 NS
NS, not signiﬁcant. Linear trends were considered in the analysis. The interim sacriﬁces included 10 animals/group with
variable numbers of animals at the 100-week sacriﬁce. 
ap-Values with marginal signiﬁcance. bNegative correlation.AHF, indicating a faster growth rate of these
AHF compared to eosinophilic AHF. This was
consistent with the study of Stauber and Bull
(1997), which treated male B6C3F1 mice with
2 g/L DCA for 38 or 50 weeks before transfer-
ring groups to 0 to 2 g/L DCA for another 2
weeks. Small AHF (> 300 cells/AHF) were pri-
marily eosinophilic, while the large AHF
(> 1,000 cells/focus and corresponding to the
LFCA) were primarily basophilic. The popula-
tion of neoplastic lesions was found to have a
significantly higher ratio of basophilic to
eosinophilic lesions (Stauber and Bull 1997),
which is similar to the ﬁndings in the present
study. As seen in Tables 3 and 4, the number
of basophilic and/or clear cell LFCA and ADs
per animal was signiﬁcantly different from con-
trols at both low and high doses of DCA, and
the development of basophilic and/or clear cell
AHF, LFCA, and ADs was related to length of
exposure and DCA dose. We interpret the data
in Figure 6 as showing the faster growth rate of
basophilic and/or clear cell lesions and time
dependence of the transformations between
lesions. Thus, at both lower and higher doses of
DCA, the number of basophilic and/or clear
cell AHF per mouse (the smallest lesions)
increased until 78 weeks. At 100 weeks the
number of basophilic and/or clear cell AHF per
mouse decreased sharply, and this decrease cor-
responded to a sharp increase in the larger
lesions, the basophilic and/or clear cell LFCA.
In contrast, the number of eosinophilic AHF
per mouse increased with increasing length of
exposure, while significant numbers of the
larger lesions, eosinophilic LFCA, never appear
(Figure 6). Thus, DCA promoted clonal
expansion of basophilic and/or clear cell lesions.
DCA also promoted neoplastic progression of
premalignant basophilic and/or clear cell
lesions: more than 48% of either the LFCA or
ADs with dysplasia or CA were basophilic
and/or clear cell (Fig. 2C). 
Richmond et al. (1991) previously
reported that LFCA in DCA-treated animals
contained foci of cells that expressed tumor
markers more frequently found in ADs and
CAs. Here the number of basophilic and/or
clear cell ADs increased at lower DCA doses
throughout the study (Figure 6). At higher
DCA doses the number of basophilic and/or
clear cell ADs per mouse increased sharply at
52 weeks, then plateaued through 100 weeks,
while the number of CAs per mouse
increased in stepwise fashion at 78 and 100
weeks, suggesting a transformation of the
basophilic and/or clear cell ADs to CAs.
The similarity in appearance of atypical
cells in non-involved liver early in control and
DCA-treated animals to those found in CAs
supports the third lesion sequence (from
atypical cells to dysplastic AHF and CAs
directly). The presence of atypical nuclei in
non-involved liver was associated with the
number of CAs per mouse even when the
data were adjusted for DCA dose and length
of exposure. Moreover, logistic regression
analysis indicated that the presence of atypical
nuclei in the non-involved liver was highly
correlated with both DCA dose and length of
exposure (Tables 6 and 7). Consistent with
these data, Stauber et al. (1998) found that
DCA promoted the outgrowth of anchorage-
independent colonies from hepatocytes iso-
lated from naive 5- to 8-week old mice above
the small number of anchorage-independent
colonies that grew out of the population of
untreated hepatocytes.
Since the present histopathologic analysis
indicates that DCA does not induce a unique
type of lesion, DCA may be acting as a non-
genotoxic carcinogen in this model. Exposure
of mice to DCA induces a multitude of toxic
and adaptive hepatic responses including
mitoinhibition, peroxisome proliferation,
glycogen accumulation, and endocrine dis-
ruption (Carter et al. 1995a; DeAngelo et al.
1999; Kato-Weinstein et al. 1998). Here we
examined the relationship of some of these
toxic and adaptive responses to DCA dose
and length of exposure and to neoplastic pro-
gression. A strong correlation between the
development of CAs and early liver weight
gain (before the development of tumors) was
found in these animals with increasing DCA
dose (DeAngelo et al. 1999). The liver weight
was a reflection of the hepatomegaly that
resulted in part from accumulation of glyco-
gen in hepatocytes (Carter et al. 1995a;
International Life Sciences Institute 1997;
Stauber et al. 1998). The incidence of glyco-
gen accumulation was dose dependent. In
mice exposed to 0.5 g/L DCA, glycogen
accumulation was seen only in the periportal
hepatocytes. At concentrations ≥ 1 g/L,
glycogen accumulation was diffuse and occu-
pied greater than 50% of the lobules.
The degree to which hepatocellular
necrosis underlies the carcinogenic process is
not fully understood, but could be signiﬁcant
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Table 7. Logistic regression analysis (p-values) of incidence of toxic or adaptive responses with length of
exposure at given doses of DCA and overall adjusted for dose (Overall adj).
Toxic/adaptive
response Control 0.5 g/L 1.0 g/L 2.0 g/L 3.5 g/L Overall adj
Necrosis NS — 0.0021a 0.0145a NS 0.0024a
Glycogen — — 0.0195 NS NS 0.0001a
Cytomegaly — NS 0.0371a 0.0991a,b  0.0910a,b 0.0027a
CA — — 0.0345 0.0006 0.0010 0.0001
Steatosis 0.0773b 0.0074 0.0350 NS NS 0.0001
Zonal change NS 0.0711b 0.0002a 0.0197a NS 0.0038
Atypical nuclei 0.0302 0.0101 0.0001 0.0002 0.0222 0.0001
Enlarged nuclei NS 0.0375 0.0001 0.0004 0.0016 0.0001
NS, not significant. Controls received 0 g/L DCA. Linear trends were considered in the analysis. The interim sacrifices
included 10 animals/group with variable numbers of animals at the 100-week sacriﬁce.
aNegative correlation. bp-Values with marginal signiﬁcance.
Table 8. Summary of recent in vitro and in vivo genotoxicity assays for dichloroacetic acid.
Activity Reference
In vitro assays
DNA alkaline unwinding assay Chang et al. 1992
Rat hepatocytes (0.128–1.28 g/L, 4 hr)a Not active
Mouse hepatocytes (0.013–1.28 g/L, 4 hr)a Not active
Prophage-induction assay (+S9; ~2 g/L)b Positive DeMarini et al. 1994
Salmonella T-100 assay (0.05 g/L)c Positive DeMarini et al. 1994
L5178Y/TK+/––3.7.2C Mouse lymphoma assay (0.8 g/L)d Positive Harrington-Brock et al. 1998
In vivo assays
DNA alkaline unwinding assay Chang et al. 1992
Mouse liver (0.64 g/kg, 4 hr)e Positive
Mouse liver (0.5 and 5 g/L, 7 and 14 days exposure) Not active
Rat liver (0.128–1.28 g/kg, 4 hr) Not active
Rat liver (2 g/L, 30 weeks exposure) Not active
Ras oncogene activation (mouse CA, 1 and 3.5 g/L,  Not active Ferreira-Gonzalez et al. 1995
100 weeks exposure)f
Mouse peripheral blood micronucleus assay Fuscoe et al. 1997
MN-PCE (3.5 g/L, 9 days exposure)g Positive
MN-PCE (3.5 g/L, 28 days exposure)h Positive
Single cell gel assay (3.5 g/L, 28 days exposure)i Positive
Lacl transgenic mouse liver (1 and 3.5 g/L, 4 and 10 weeks)j Negative Leavitt et al. 1997
aConcentration range, 4-hr treatment. bLowest effective concentration that produced a 3-fold increase in plaque-forming
units/plate relative to the background. cLowest effective concentration that produced a 2-fold increase in reversions/plate
relative to the background. dConcentration required to give a response equal to 0.013 g/L methylmethanesulfonate. eLowest
dose producing significant DNA damage (1.08-fold). fNo increase in the percent ras mutations in DCA-induced tumors
when compared to tumors from untreated mice. gLowest DCA concentration giving a positive response (1.8-fold). hLowest
DCA concentration giving a positive response (1.3-fold). iLowest DCA concentration giving a positive response. jNo
increased lacl mutations in the livers from DCA treated mice when compared to livers from control animals.at higher DCA concentrations (≥ 1g/L). The
extent of necrosis in animals exposed to 0.5
g/L measured both in this study and in a pre-
vious analysis (International Life Sciences
Institute 1997) was confined to individual
hepatocyes and small clusters of cells. The
overall prevalence of both glycogen accumu-
lation and necrosis was less than the overall
prevalence of CAs (Table 5). Whereas dys-
plastic AHF, dysplastic LFCA, and dysplastic
ADs were not associated with necrosis, dys-
plastic ADs were associated with glycogen
accumulation. Overall, both glycogen accu-
mulation and necrosis were negatively corre-
lated with length of DCA exposure (Table
7), indicating adaptation in non-involved
hepatocytes.
DCA also resulted in adaptive changes in
lipid metabolism in the non-involved hepato-
cytes of mice chronically exposed to DCA, as
evidenced by an inhibition of steatosis (lipido-
sis) (Table 6). Steatosis was negatively associ-
ated with both dysplastic LFCA and CA.
Presumably, many other alterations in hepatic
metabolism occur in DCA-treated mice as a
result of endocrine disruption. Moore and
DeAngelo (1997) reported that, during DCA-
induced carcinogenesis, both serum corticos-
teroid levels and hepatic 11β-hydroxysteroid
dehydrogenase (the enzyme that catalyses the
conversion of corticosterone to 11-deoxycorti-
costerone) were increased in a dose- and time-
dependent manner. At the same time that
DCA altered serum corticosterone levels, it
also altered the binding activity and subcellu-
lar localization of the cytoplasmic and nuclear
glucocortcoid receptor in mouse liver
(DeAngelo and McFadden 1995).
Generalized hepatocyte mitoinhibition
was characteristic of DCA treatment (Carter
et al. 1995a; DeAngelo 2000a; Stauber and
Bull 1997). Early mitoinhibition was both
dose- and time-dependent in vivo and was a
direct effect of DCA because it occurred in
isolated hepatocytes in vitro (Carter et al.
1995a; DeAngelo 2000a). Mitoinhibition
was accompanied by a suppression in sponta-
neous apoptosis in non-involved hepatocytes
(Snyder et al. 1995). By selective toxicity on
normal hepatocytes, DCA may be promoting
the outgrowth of cells either resistant to
mitoinhibition (basophilic AHF) or able to
metabolize DCA to non-mitoinhibitory
products (eosinophilic AHF). The presence of
necrosis could further enhance clonal expan-
sion of cells resistant to DCA mitoinhibition.
Recent data indicated that dose-dependent
DCA-induced mitoinhibition was also found
in premalignant hepatic lesions as well as a
progressive dysregulation of p39 c-jun expres-
sion (Carter et al. 2001a, 2001b).
When considered together, these data sug-
gest that DCA acts to alter the homeostasis of
hepatocytes, leading to negative selection of
cells with a new state of differentiation resis-
tant to DCA toxicity. These effects of DCA
are dose dependent and occur at concentra-
tions < 1 g/L, which is the inﬂection point of
the dose–response curve for carcinogenesis.
DCA-induced suppression of apoptosis, the
natural process for eliminating initiated cells,
would increase the growth and/or survival of
these preneoplastic cells and lesions. The
strong associations found here between the
occurrence of atypical cells in non-involved
liver and dysplastic LFCA (p = 0.0001), dys-
plastic AD (p = 0.0074) and CA (p = 0.0136)
are consistent with this conclusion.
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